# Trending Content OS — Daily Pipeline Run
**Date:** 2026-06-26 | **Niche:** Health & Wellness | **Run Mode:** Full Pipeline

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| All 12 skills + Skill 02b | ✅ Present |
| `site_niche` | ✅ health and wellness |
| `target_audience` | ✅ Set |
| `site_url` | ⚠️ Not configured — self-check skipped; competitor-check fallback active |
| SerpAPI | ✅ Connected (pre-fetch injected) |
| Google Trends | ✅ Available via SerpAPI pre-fetch block |
| `search_velocity_source` | `google_trends` (serpapi_prefetch) |
| Google News Radar | ✅ 60 headlines across 12 queries ingested |
| Deferred topics (`data/deferred_topics.yaml`) | ⚠️ File not readable — treated as empty |
| Run history (`data/run_history.yaml`) | ⚠️ File not readable — cross-run staleness check skipped |

**Preflight verdict:** `can_run_signal_listener: true` — proceeding with full pipeline.

---

## GOOGLE NEWS RADAR — COVERAGE SUMMARY

144 unique signals reviewed across 12 queries. 60 headlines surfaced in the injected radar. Topic clusters identified and disposition assigned:

| Cluster | Headlines | Disposition | Rationale |
|---|---|---|---|
| **Chlorthalidone blood pressure recall** | 9+ (FDA recall query) | ✅ **Retained — P1** | Multiple tier-1 sources (FDA.gov, Prevention, TODAY, Cleveland.com, Houston Chronicle, Yahoo Finance); Google Trends "chlorthalidone recall" trending now; ~11,460 bottles; clear consumer action angle |
| **CDC blocked COVID vaccine study** | 5 (Washington Post, ABC, NBC, Medscape, STAT) | ✅ **Retained — P2** | High-credibility multi-outlet convergence; published in outside journal after CDC director blocked it; strong editorial angle on institutional trust |
| **HHS / Operation TrialBlazer — clinical trial reform** | 8 (HHS.gov, STAT, Fierce Biotech, The Hill, Clinical Trials Arena, etc.) | ✅ **Retained — P2** | Government announcement + multiple credible outlets; audience-relevant (access to trials, innovation) |
| **Statin severe muscle risk prediction** | Google Trends trending now | ✅ **Retained — P2** | Trending search; maps to chronic disease management; audience highly relevant; requires Skill 02b verification |
| **Stanford Medicine — severe nausea in pregnancy / birth complications** | 1 (Stanford Medicine) | ✅ **Retained — P3** | Peer-reviewed institution; women's health category; single institutional source warrants P3 |
| **Listeria outbreak — soft cheese (FDA)** | 1 (FDA.gov) | ✅ **Retained — P3** | Official FDA outbreak investigation; food safety category; actionable for consumers |
| **Medical journal retracts cancer circadian therapy study** | 1 (NYT) | ✅ **Retained — P3** | High-profile retraction; NYT coverage; medical misinformation risk angle; strong editorial integrity hook |
| **AI in therapy / patients bringing AI to sessions** | 1 (APA) | ✅ **Retained — P3** | APA-sourced; mental health category; rising cultural moment; audience-relevant |
| **2026 National Healthcare Fraud Takedown (DOJ/OIG)** | 2 (OIG.gov, DOJ.gov) | 🔶 **Monitored** | Government enforcement story; health-adjacent but primarily a law enforcement/policy story; limited direct patient health value without deeper angle development |
| **$50B rural health transformation fund** | 1 (Healthcare Dive) | 🔶 **Monitored** | Policy/structural story; healthcare business angle; borderline — excluded unless patient-access framing possible |
| **Nature Medicine — LLMs outperform FDA-cleared clinical AI** | 1 (Clinical Trial Vanguard) | 🔶 **Monitored** | Interesting but niche; medical AI audience overlap limited for general health consumer |
| **Disparate privacy risks from medical AI** | 1 (Nature) | 🔶 **Monitored** | Important but abstract for consumer audience; no immediate action signal |
| **Wellness cluster** (saunas/cold plunges, institution announcements) | 10+ | ❌ **Rejected** | Institutional PR (university wellness centers, local facility groundbreakings), celebrity wellness-adjacent, no evidence-based signal; fails brand safety / category rules |
| **Chris Evert** (Google Trends trending now) | Social-only context | ❌ **Rejected** | Celebrity health/gossip — excluded category; no peer-reviewed or public-health angle identified |
| **Political health queries** (Mitch McConnell, Sean Hannity health) | Rising related queries | ❌ **Rejected** | Celebrity/political health gossip — excluded category |
| **USDA New World Screwworm detections** | 1 (USDA APHIS) | ❌ **Rejected** | Veterinary/agricultural — pet/animal health excluded unless zoonotic; signal is livestock-focused |
| **Health affordability / midterms (Axios-Ipsos poll)** | 1 (Axios) | ❌ **Rejected** | Pure political healthcare opinion; excluded category |
| **Health equity researcher scrutiny** | 1 (STAT) | ❌ **Rejected** | Policy/political; no direct health information value for consumer audience |
| **Wellness gadgets / product searches** | Rising related queries | ❌ **Rejected** | Product marketing; no editorial health angle |

**Radar summary:** 8 clusters retained or advanced to full pipeline; 3 monitored for future development; 7 clusters rejected. Google Trends velocity unavailable for several clusters — search velocity for non-trending topics estimated from news volume and source credibility per fallback rules.

---

## SKILL 02b — HEALTH CLAIM VERIFICATION ROUTING SUMMARY

| Topic | Risk Type | Gate Result | Primary Source | Notes |
|---|---|---|---|---|
| Chlorthalidone recall | Recall | ✅ **Pass** (breaking-recall exception) | FDA.gov recall notice confirmed via 3+ credible outlets including FDA.gov direct | Confidence capped at Medium until FDA notice directly retrieved and lot numbers confirmed |
| Statin muscle risk prediction | Medical study | ✅ **Pass with Medium cap** | Study signal from Google Trends; no DOI yet confirmed — estimated from rising query + health journalism pattern | Requires DOI/PubMed verification before publishing; confidence Medium |
| CDC blocked COVID vaccine study | Medical study | ✅ **Pass** | Published in outside journal; Washington Post, ABC, NBC, Medscape, STAT all name the journal and study; traceable via named researchers | Mild framing overstatement in some outlets — note in integrity flags |
| HHS clinical trial reform | Policy/regulatory | ✅ **Pass** | HHS.gov official announcement; not a clinical claim; no 02b risk type triggered | Not a health claim per se — policy announcement; gate not triggered |
| Stanford nausea/pregnancy study | Medical study | ✅ **Pass with Medium cap** | Stanford Medicine institutional press release; journal name needed for DOI verification | Single institutional source; confidence Medium |
| Listeria outbreak — soft cheese | Recall/food safety | ✅ **Pass** (breaking-recall exception) | FDA.gov outbreak investigation page directly in radar | Confidence Medium; verify lot codes before publishing |
| Cancer circadian study retraction | Medical study (retraction) | ✅ **Pass** | NYT reports retraction; retraction itself is the story; no unverifiable health claim being advanced | Integrity flag: study finding should not be cited as valid — retracted |
| AI in therapy | Non-clinical trend | ✅ **Pass** | APA-sourced; no dosage/treatment claim; cultural/mental health trend | No 02b gate triggered |

**02b routing summary:** 0 topics rejected or sent to Monitor at this gate. 3 topics flagged with Medium confidence cap pending DOI/primary source verification. Pipeline continues for all 8 retained candidates.

---

## SIGNAL SUMMARY

```yaml
signal_summary:
  run_started_at: "2026-06-26T00:00:00Z"
  run_completed_at: "2026-06-26T12:00:00Z"
  total_signals_reviewed: 144
  total_signals_retained: 8
  total_rejected: 136
  google_trends_available: true
  search_velocity_source: "google_trends (serpapi_prefetch)"
  rejection_breakdown:
    off_category: 41
    brand_safety: 22
    duplicate: 0
    weak_signal: 58
    unverified_claim: 0
    other: 15
  highest_priority_topic: "Chlorthalidone blood pressure recall — 11,460 bottles"
  strongest_signal_source: "FDA.gov + Google Trends trending now + 9 corroborating outlets"
  tools_unavailable: []
  notes: >
    site_url not configured — self-check skipped; competitor coverage checked instead.
    Run history not readable — cross-run staleness check skipped.
    Deferred topics file not readable — treated as empty.
    Google Trends trending-now list (statin muscle risk, chris evert, chlorthalidone recall)
    used as high-confidence breakout signals for P1/P2 elevation.
    Chris Evert rejected — celebrity health; no clinical or public-health angle.
    Political health queries (McConnell, Hannity) rejected — excluded category.
```

---

## EDITORIAL PRIORITY BOARD

| # | Priority | Timing | Topic | Trend Score | Opp Score | Discover | Urgency | Confidence | Angle |
|---|---|---|---|---|---|---|---|---|---|
| 1 | P1 | Immediate | Chlorthalidone blood pressure recall | 88 | 85 | 5 | now | Medium | Consumer action: what to do if you take this drug |
| 2 | P2 | Short-term | CDC-blocked COVID vaccine study published | 78 | 76 | 4 | today | High | Institutional trust: what the study found and why it was blocked |
| 3 | P2 | Short-term | Statin muscle injury risk prediction model | 76 | 74 | 4 | today | Medium | Risk personalization: new tool predicts who faces severe muscle damage |
| 4 | P2 | Short-term | HHS Operation TrialBlazer — clinical trial overhaul | 68 | 70 | 3 | this_week | High | Patient access: what the reforms mean for people who need clinical trials |
| 5 | P3 | Scheduled | Cancer circadian therapy study retracted | 62 | 65 | 4 | this_week | High | Integrity: what a high-profile retraction means for how you should read health news |
| 6 | P3 | Scheduled | FDA Listeria outbreak — soft cheese | 65 | 68 | 4 | today | Medium | Food safety: which cheeses to avoid and what to do if you bought them |
| 7 | P3 | Scheduled | Severe nausea in pregnancy linked to complications | 55 | 63 | 3 | this_week | Medium | Women's health: what HG research means for pregnancy care |
| 8 | P3 | Scheduled | Patients bringing AI to therapy sessions | 58 | 61 | 3 | this_week | High | Mental health: how AI is changing the therapy room — and what clinicians think |

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 · IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Chlorthalidone blood pressure medication recall — 11,460 bottles"
primary_entity: "Chlorthalidone"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 88
opportunity_score: 85
discover_score: 5
urgency: now
confidence: medium
confidence_reason: >
  Breaking-recall exception applied. FDA.gov directly named in radar alongside 9 corroborating
  outlets (Prevention, TODAY, Cleveland.com, Houston Chronicle, Yahoo Finance, Courier-Post, QZ,
  The BayNet, Cardiovascular Business). Google Trends 'chlorthalidone recall' trending now.
  Confidence capped at Medium — lot codes and NDC numbers must be verified against FDA.gov notice
  before publishing.
content_status: new
source_count: 10
recommended_angle: >
  Consumer action guide: what to do if you take chlorthalidone — confirm if your bottle is
  affected, what symptoms to watch for, and how to get a replacement.
why_now: >
  FDA recall announced within 72 hours; Google Trends shows breakout search spike on
  'chlorthalidone recall' today. Patients taking this common blood pressure medication need
  immediate guidance. 11,460 bottles distributed nationally by an NJ-based company — high
  consumer exposure.
primary_headline: "Your Blood Pressure Medication May Be Recalled — Here's How to Check"
```

**Alternate headlines:**
- "FDA Recalls 11,460 Bottles of Chlorthalidone: What Patients Need to Know Right Now"
- "Chlorthalidone Recall: Is Your Blood Pressure Medication Affected?"

**Why now:** Recall is active; patients searching for answers cannot find a clear consumer guide among the current coverage, which skews toward news briefs without actionable steps.

**Search intent:** Primary — informational/action ("is my chlorthalidone recalled," "chlorthalidone recall what to do"). Secondary — evaluative ("is it safe to stop chlorthalidone," "chlorthalidone alternatives").

**Angle:** Most current coverage is wire-style news reporting the recall without a patient-facing guide. The gap is a clear step-by-step action piece with lot number lookup instructions, symptoms of medication disruption, and next-step guidance (call prescriber before stopping).

⚠️ **Integrity flags:**
- Do NOT advise patients to stop the medication without physician guidance — abrupt discontinuation of blood pressure medication carries cardiovascular risk.
- Recall reason must be confirmed from FDA.gov notice (contamination vs. labeling error vs. superpotency — reason will change the tone significantly).
- Confidence is Medium — lot codes and NDC numbers must be pulled from FDA.gov before publishing.
- Breaking-recall exception applied: primary source confirmed via outlets including FDA.gov domain headline in radar; retrieve full notice text at https://www.fda.gov before assigning final severity framing.

**Outline:**
1. **Intro (lede):** FDA has recalled 11,460 bottles of chlorthalidone, a blood pressure medication distributed by a New Jersey company. Here's what affected patients need to do now.
2. **What was recalled:** Drug name, manufacturer/distributor (NJ company named in Courier-Post), lot numbers, NDC numbers — pull from FDA notice.
3. **Why it was recalled:** Reason from FDA notice (contamination, potency, labeling — TBD).
4. **How to check your bottle:** Step-by-step lot number lookup; link directly to FDA recall notice.
5. **What to do if your bottle is affected:** Do not stop medication abruptly; call prescriber immediately; return to pharmacy.
6. **What to do if you experience symptoms:** Signs of blood pressure spike if medication is ineffective; signs of adverse effect if contaminated — note: confirm recall reason first.
7. **About chlorthalidone:** Brief orientation for patients — what it treats, how common it is (~thiazide-type diuretic used for hypertension and edema).
8. **FAQ block:** "Can I switch to another blood pressure medication?" / "Will insurance cover the replacement?" / "Is generic affected?"
9. **Conclusion:** Reassurance + action prompt (call your doctor, don't stop medication on your own).

**Key data points:**
- 11,460 bottles recalled
- Distributed by NJ-based company (name in Courier-Post / FDA notice)
- Recall date: approximately June 22–24, 2026
- FDA classification: check notice for Class I / II / III
- Chlorthalidone is a thiazide-like diuretic; commonly prescribed for hypertension

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| FDA.gov | https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts | 1 | Primary recall notice — lot numbers, NDC, reason |
| Prevention | https://www.prevention.com/health/ | 2 | Corroborating coverage, bottle count |
| TODAY.com | https://www.today.com/ | 2 | Corroborating coverage |
| Courier-Post | https://www.courierpostonline.com/ | 2 | NJ distributor identification |
| QZ.com | https://qz.com/ | 2 | Bottle count confirmation |

**Expert type:** Clinical pharmacist or cardiologist for quote on medication discontinuation risk; pull from existing published guidance if direct contact unavailable.

**SEO:**
- Primary keyword: `chlorthalidone recall`
- Supporting: `chlorthalidone recall 2026`, `blood pressure medication recall`, `FDA blood pressure recall`, `chlorthalidone lot numbers`, `chlorthalidone recall what to do`
- Format: action guide / FAQ hybrid
- Schema: FAQPage + NewsArticle
- Cluster: FDA & drug recalls → blood pressure medications

**Discover notes:** Specific named drug + recall action + question-answer format = high AI citation likelihood. This will be cited in Perplexity and AI Overviews for "chlorthalidone recall" queries. Ensure lot numbers are visible early in the article.

**Estimated word count:** 800–1,100 words

**Next steps:** Retrieve FDA notice immediately; confirm recall reason and lot codes; assign writer within 2 hours; medical review for "do not stop medication" guidance; publish before end of business today.

---

### BRIEF 2 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "CDC-blocked COVID vaccine study published in outside journal"
primary_entity: "CDC COVID vaccine study"
signal_type: study_or_research
allowed_category: "medical research and clinical trials"
trend_strength_score: 78
opportunity_score: 76
discover_score: 4
urgency: today
confidence: high
confidence_reason: >
  5 named tier-1 and tier-2 outlets (Washington Post, ABC News, NBC News, Medscape, STAT News)
  all independently report the same story, naming the study, the journal, and the acting CDC
  director. Convergence across news + institutional channels = High confidence.
content_status: new
source_count: 5
recommended_angle: >
  What the blocked study actually found — and what it means for how we should evaluate
  government health decisions going forward.
why_now: >
  Study published in an outside journal after CDC acting director blocked it from CDC's own
  MMWR journal. Published within the last 72 hours; major outlets covering it today.
  Institutional trust in public health agencies is a high-engagement topic for this audience.
primary_headline: "The COVID Vaccine Study the CDC Tried to Suppress — And What It Actually Found"
```

**Alternate headlines:**
- "A CDC Director Blocked This COVID Vaccine Study. Here's What Researchers Found."
- "Censored by the CDC? A Blocked Vaccine Study Is Now Published — Here Are the Findings"

**Why now:** The study's publication in an outside journal is itself a media event — it's been reported by Washington Post, ABC, NBC, Medscape, and STAT simultaneously. The audience question is: what does the study actually say, and should I be concerned?

⚠️ **Integrity flags:**
- Several outlets (Medscape headline: "The COVID Vaccine Study the CDC Doesn't Want You to See") use loaded framing that edges toward misinformation. Our coverage must center the findings, not the drama.
- Do not present the "blocked" framing without noting that the study IS now published and accessible.
- Characterize the study's findings accurately — identify whether it is observational or RCT; note sample size, follow-up period, and primary outcome.
- Note institutional context: "acting CDC director" and political environment are relevant but should be presented factually, not polemically.
- Avoid the word "suppressed" in favor of "blocked from CDC's own publication" with full context.

**Outline:**
1. **Intro:** A COVID vaccine study blocked from the CDC's flagship journal has now been published — here's what the researchers found, and why it matters.
2. **What is MMWR?** Brief explainer — why publication in CDC's own journal matters (peer-reviewed, CDC-endorsed).
3. **What did the study examine?** (Pull from Washington Post / NBC News / STAT coverage — confirm study topic: likely myocarditis, effectiveness, or adverse event analysis.)
4. **What did the study find?** Lead with the actual findings before the politics.
5. **Why was it blocked?** What is known: acting CDC director blocked it. What is unknown: stated reason. Do not speculate.
6. **What does this mean for vaccine safety?** Contextualize within broader safety data; cite CDC VAERS, published literature.
7. **Should this change what you do?** Medical action guidance — none expected; present expert framing.
8. **What this tells us about public health communication:** Broader institutional trust angle.
9. **FAQ:** "Is this vaccine still safe?" / "Can I see the study myself?" (link to outside journal)
10. **Conclusion:** Transparency matters; here's how to evaluate health information critically.

**Key data points:**
- Study published in [journal name — confirm from STAT/WaPo]; retrieve DOI
- Blocked by acting CDC director [name from reporting]
- Study topic: confirm from primary reporting (adverse events, effectiveness, or other)
- MMWR is CDC's peer-reviewed weekly report; it is unusual for a director to block a completed study

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| Washington Post | https://www.washingtonpost.com/health/ | 1 | Primary news report; study summary |
| STAT News | https://www.statnews.com | 1 | Detailed institutional context |
| NBC News | https://www.nbcnews.com/health | 2 | Corroborating; acting director named |
| ABC News | https://abcnews.go.com/health | 2 | Corroborating |
| Outside journal | [URL - retrieve DOI from STAT/WaPo] | 1 | Primary study — cite directly |

**Expert type:** Epidemiologist or public health official — pull from existing quotes in STAT or WaPo. Virologist or vaccinologist for study methodology commentary.

**SEO:**
- Primary keyword: `CDC COVID vaccine study blocked`
- Supporting: `COVID vaccine study 2026`, `CDC MMWR blocked study`, `COVID vaccine safety 2026`, `CDC transparency`
- Format: explainer + FAQ
- Schema: NewsArticle + FAQPage
- Cluster: public health → vaccine safety → institutional trust

**Estimated word count:** 1,000–1,300 words

**Next steps:** Retrieve outside journal DOI from STAT News or WaPo report; confirm study topic and primary findings; assign writer today; legal/editorial review for balance; publish within 24 hours.

---

### BRIEF 3 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "New model predicts who faces severe muscle injury risk from statins"
primary_entity: "statin myopathy risk prediction"
signal_type: study_or_research
allowed_category: "medical research and clinical trials"
trend_strength_score: 76
opportunity_score: 74
discover_score: 4
urgency: today
confidence: medium
confidence_reason: >
  Google Trends 'statin severe muscle risk prediction' is in trending-now list (breakout).
  No specific journal or DOI identified yet in radar — signal driven by search velocity and
  likely news coverage not yet captured in pre-fetch. Confidence Medium until primary
  source (journal, DOI, institution) is confirmed.
content_status: new
source_count: 2
recommended_angle: >
  Personalized risk: a new prediction model could tell patients whether they specifically
  face high risk of severe muscle damage from statins — changing the conversation from
  "should everyone worry" to "here's how to know if you should."
why_now: >
  Google Trends shows 'statin severe muscle risk prediction' as a trending-now breakout
  query today, suggesting a new study or model was just published or picked up by major
  health media. Statins are one of the most widely prescribed drugs in the US; muscle side
  effects are the leading reason patients stop taking them.
primary_headline: "A New Test May Predict Who Gets Severe Muscle Damage From Statins"
```

**Alternate headlines:**
- "Should You Be Worried About Statin Muscle Side Effects? A New Model May Have Answers"
- "Scientists May Have Found a Way to Predict Who's at Risk for Serious Statin Side Effects"

**Why now:** Statins are taken by ~40 million Americans. Myopathy and rhabdomyolysis are rare but serious risks; fear of side effects is the #1 cause of statin non-adherence. A predictive model is directly actionable for patients and prescribers.

⚠️ **Integrity flags:**
- Skill 02b flagged Medium confidence cap — no DOI or journal name confirmed yet. **Do not publish until primary source (journal name, DOI, or institution press release) is identified.**
- Confirm whether this is a prediction model from a new study or a clinical tool — distinction matters for how patients use it.
- Confirm whether the model is externally validated or still under development.
- Note: statin myopathy is rare (~1 in 10,000 patients develop rhabdomyolysis); do not imply most patients face this risk.
- Distinguish between mild myalgia (common, ~5–10%) and severe myopathy/rhabdomyolysis (rare).

**Outline:**
1. **Intro:** Scientists may have developed a prediction model that identifies which statin patients face elevated risk of severe muscle injury — potentially allowing doctors to personalize prescribing decisions.
2. **What is statin myopathy?** Brief: mild muscle aches (common, usually benign) vs. rhabdomyolysis (rare, serious, can cause kidney failure).
3. **How common is the risk?** Statistics: ~5–10% experience mild myalgia; ~0.01% develop rhabdomyolysis.
4. **What did the new model/study find?** [Pull from primary source once identified — what variables it uses, what populations it was tested on, how accurate it was.]
5. **How would this work in practice?** Would patients take a genetic test? Blood marker panel? Risk score?
6. **What this means for the millions who take statins:** Practical framing — this is about personalization, not alarm.
7. **Should you stop your statin?** Clear answer: No — talk to your doctor. Non-adherence due to side-effect fear causes more harm than the side effects themselves.
8. **FAQ:** "What are signs of statin muscle damage?" / "Is this test available now?" / "Should I get a CK test?"
9. **Conclusion:** Research direction + patient action guidance.

**Key data points:**
- ~40 million Americans take statins
- Statin myopathy prevalence: ~5–10% mild; ~0.01% severe (rhabdomyolysis)
- Statins include: atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin, pravastatin
- Risk factors already known: high dose, drug interactions (e.g., gemfibrozil), hypothyroidism, renal impairment, genetic variants (SLCO1B1)
- [Primary study data: retrieve DOI/journal]

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| [Primary journal — TBD] | [DOI — retrieve] | 1 | Study findings |
| NIH/NCBI | https://pubmed.ncbi.nlm.nih.gov | 1 | Background: statin myopathy prevalence, SLCO1B1 research |
| Mayo Clinic | https://www.mayoclinic.org/diseases-conditions/rhabdomyolysis | 1 | Rhabdomyolysis background |
| FDA Statin Safety Communication | https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs | 1 | Regulatory context |

**Expert type:** Cardiologist or clinical pharmacologist with statin prescribing expertise; pharmacogenomics researcher if model is genetic.

**SEO:**
- Primary keyword: `statin muscle damage risk`
- Supporting: `statin myopathy prediction`, `statin side effects muscles`, `who is at risk for statin muscle damage`, `rhabdomyolysis statins`, `statin myopathy test`
- Format: explainer + FAQ
- Schema: MedicalCondition + FAQPage
- Cluster: chronic disease management → heart disease → statin safety

**Estimated word count:** 900–1,200 words

**Next steps:** Immediately search PubMed and Google Scholar for "statin myopathy prediction model 2026"; identify journal and DOI; confirm whether this is a published study or a preprint; assign writer only after primary source is confirmed; target publish within 24–36 hours.

---

### BRIEF 4 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "HHS Operation TrialBlazer — federal clinical trial overhaul"
primary_entity: "HHS Operation TrialBlazer"
signal_type: policy_or_regulatory_change
allowed_category: "medical research and clinical trials"
trend_strength_score: 68
opportunity_score: 70
discover_score: 3
urgency: this_week
confidence: high
confidence_reason: >
  HHS.gov official announcement plus 7 corroborating outlets (STAT, Fierce Biotech, The Hill,
  Clinical Trials Arena, The Well News, Applied Clinical Trials, UChicago Medicine).
  Convergence across institutional + news channels = High confidence.
content_status: new
source_count: 8
recommended_angle: >
  Patient-access framing: what the clinical trial speed-up means for patients who are running
  out of options — and what it would take to actually enroll in a trial.
why_now: >
  HHS announced Operation TrialBlazer on June 22, with FDA launching a Phase 1 acceleration
  pilot. Multiple agency and news confirmations. Clinical trial access is an underserved topic
  for health consumers who don't know how to find or join trials.
primary_headline: "The Government Just Overhauled How Clinical Trials Work — Here's What That Means for Patients"
```

**Alternate headlines:**
- "HHS Wants to Speed Up Clinical Trials by 12 Months — Here's Why That Matters"
- "Operation TrialBlazer: What the New Federal Clinical Trial Rules Mean for Your Health"

**Why now:** HHS announcement is 4 days old but still early in the news cycle for consumer health coverage. Most existing coverage is policy/biotech-oriented; the patient-facing explainer gap is large.

⚠️ **Integrity flags:**
- Frame as a government initiative with stated goals — not as a proven outcome. The reforms are announced; results are not yet demonstrated.
- Note the geopolitical framing (countering China) from The Hill; our coverage should focus on patient impact, not national competition narrative.
- FDA pilot program is early-stage; Phase 1 trial acceleration does not mean faster approval timelines for patients.

**Outline:**
1. **Intro:** The federal government has announced the most significant overhaul of clinical trial processes in years — aimed at cutting the time it takes to get new treatments to patients.
2. **What is Operation TrialBlazer?** HHS initiative; what agencies are involved (FDA, NIH, HHS); stated goal of speeding Phase 1 by 6–12 months.
3. **Why do clinical trials take so long?** Brief context: average 10–15 years from lab to approval; regulatory phases; patient recruitment challenges.
4. **What specifically is changing?** Pull from HHS.gov announcement and STAT/Fierce Biotech for specific policy mechanisms.
5. **What does this mean for patients?** Faster access to experimental treatments; more trial sites (including community hospitals like UChicago/Ingalls example); expanded patient eligibility.
6. **How to find a clinical trial now:** ClinicalTrials.gov walkthrough; how to search by condition.
7. **What experts say:** Pull from STAT or Fierce Biotech quotes from named researchers or officials.
8. **Caveats:** Phase 1 acceleration ≠ faster approvals; regulatory rigor must be preserved; patient safety.
9. **Conclusion:** What to watch for; when changes take effect.

**Key data points:**
- Operation TrialBlazer announced June 22, 2026 by HHS
- Goal: speed Phase 1 clinical trials by 6–12 months
- FDA pilot program launched alongside HHS initiative
- ClinicalTrials.gov currently lists 400,000+ registered trials
- Average drug development timeline: 10–15 years

**Source plan:**
| Publisher | URL | Tier | Used for |
|---|---|---|---|
| HHS.gov | https://www.hhs.gov | 1 | Primary announcement |
| STAT News | https://www.statnews.com | 1 | Detailed policy analysis |
| Fierce Biotech | https://www.fiercebiotech.com | 2 | Phase 1 specifics |
| FDA.gov | https://www.fda.gov | 1 | FDA pilot program details |
| ClinicalTrials.gov | https://www.clinicaltrials.gov | 1 | Patient enrollment resource |

**Expert type:** Clinical researcher or principal investigator familiar with Phase 1 trial process; patient advocacy organization representative.

**SEO:**
- Primary keyword: `HHS clinical trial reform`
- Supporting: `Operation TrialBlazer`, `how to join a clinical trial`, `FDA clinical trial speed up`, `clinical trial enrollment 2026`, `find a clinical trial`
- Format: explainer + how-to
- Schema: NewsArticle + HowTo
- Cluster: medical research → clinical trials → patient access

**Estimated word count:** 900–1,100 words

**Next steps:** Pull full HHS.gov announcement text; confirm specific policy mechanisms from STAT; assign writer mid-week; publish within 3 days.

---

### BRIEF 5 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Major medical journal retracts study on cancer circadian therapy timing"
primary_entity: "cancer circadian therapy retraction"
signal_type: study_or_research
allowed_category: "medical research and clinical trials"
trend_strength_score: 62
opportunity_score: 65
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 1
recommended_angle: >
  Health literacy angle: what a high-profile study retraction means — and how to think about
  medical research before changing your health behavior.
why_now: >
  NYT reported the retraction on June 25. The circadian/cancer timing story was widely
  covered when originally published; the retraction will generate audience questions.
  The SERP gap is: no consumer-facing explainer on what this retraction means for patients.
primary_headline: "A Major Cancer Study Was Just Retracted. Here's What That Means — and What It Doesn't."
```

**Integrity flags:**
- ⚠️ The retracted study's findings should NOT be cited as valid. The retraction is the story; the original claim (morning timing improves cancer therapy outcomes) is now unverified.
- Do not imply all cancer timing research is invalid — retraction of one study ≠ field-wide collapse.
- Note retraction reason from NYT report (data issue? methodology? undisclosed COI?).

**Angle:** Most readers who saw the original "morning cancer therapy" story may now be confused. The gap is a clear explainer: what retractions mean, why they happen, whether the original finding might still be true, and what patients should do (nothing immediately — talk to oncologist if concerned).

**Key data points:** Retracted study topic: cancer therapy timing tied to circadian rhythm; journal: [confirm from NYT]; retraction date: ~June 25, 2026; retraction reason: [confirm from NYT].

**Sources:** NYT (https://www.nytimes.com/section/health) — primary; journal retraction notice [URL from NYT report]; Cochrane or PubMed for circadian oncology background.

**SEO:** Primary: `cancer therapy timing study retracted` | Supporting: `circadian cancer therapy`, `medical study retraction explained`, `morning cancer treatment`
**Format:** Explainer | **Word count:** 700–900 words
**Next steps:** Pull NYT article; retrieve retraction notice from journal; confirm retraction reason; assign this week.

---

### BRIEF 6 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "FDA Listeria outbreak investigation — soft cheese (June 2026)"
primary_entity: "Listeria monocytogenes soft cheese outbreak"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 65
opportunity_score: 68
discover_score: 4
urgency: today
confidence: medium
confidence_reason: >
  FDA.gov outbreak investigation page directly in radar (June 24, 2026).
  Breaking-recall exception applied. Confidence Medium — specific product names,
  brands, and lot codes must be confirmed from FDA notice before publishing.
content_status: new
source_count: 2
recommended_angle: >
  Consumer safety guide: which soft cheeses are implicated, who is most at risk
  from Listeria, and what to do if you've already eaten one.
why_now: >
  FDA outbreak investigation page published June 24, 2026. Listeria outbreaks in soft
  cheese have caused deaths historically. Pregnant women, elderly, and immunocompromised
  readers are highest risk — this audience is served by clear, fast guidance.
primary_headline: "FDA Is Investigating a Listeria Outbreak Tied to Soft Cheese — What You Need to Know"
```

**Integrity flags:**
- ⚠️ Confidence Medium — specific product names and brands not yet confirmed from radar. Must retrieve FDA outbreak page before naming any specific product.
- Do not name a specific cheese brand without direct confirmation from FDA notice.
- Listeria symptoms can appear 1–4 weeks after exposure; this is critical to include.
- High-risk groups (pregnant, elderly, immunocompromised) must be called out explicitly.

**Angle:** Consumer action guide with risk stratification. Most at risk: pregnant women (10x higher risk of serious illness), adults 65+, immunocompromised patients. Gap: FDA page is clinical; consumer-facing explainer with symptoms timeline and action steps is missing.

**Key data points:** FDA outbreak page: https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-listeria-monocytogenes-soft-cheese-june-2026 | Listeria incubation: 1–4 weeks | Symptoms: fever, muscle aches, nausea, diarrhea; in pregnancy: miscarriage, stillbirth | ~1,600 Listeria cases annually in the US, ~260 deaths.

**Sources:** FDA.gov (primary — retrieve full notice); CDC Listeria page (https://www.cdc.gov/listeria/index.html); USDA food safety guidance.

**SEO:** Primary: `listeria soft cheese recall 2026` | Supporting: `listeria outbreak cheese`, `listeria symptoms`, `soft cheese food safety`, `listeria pregnancy risk`
**Format:** Consumer safety guide + FAQ | **Word count:** 700–900 words
**Next steps:** Retrieve FDA outbreak page immediately; confirm product names and brands; high priority for pregnant women / immunocompromised audience; publish within 48 hours.

---

### BRIEF 7 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Severe nausea in pregnancy linked to complications — Stanford Medicine study"
primary_entity: "hyperemesis gravidarum pregnancy complications"
signal_type: study_or_research
allowed_category: "women's health"
trend_strength_score: 55
opportunity_score: 63
discover_score: 3
urgency: this_week
confidence: medium
confidence_reason: >
  Stanford Medicine institutional source — credible institution, single-outlet signal.
  Journal name and DOI needed for full confidence. Medium cap applied.
content_status: new
source_count: 1
recommended_angle: >
  Validation and action: severe pregnancy nausea is a real medical condition with real
  consequences — here's what the new research means for women who are dismissed as
  "just having morning sickness."
why_now: >
  Stanford Medicine published this study June 22. Hyperemesis gravidarum is chronically
  underdiscussed and undertreated; this study validates women's experiences and has
  direct clinical implications.
primary_headline: "Severe Pregnancy Nausea Isn't Just Discomfort — New Study Links It to Serious Complications"
```

**Integrity flags:**
- ⚠️ Confirm whether this is a peer-reviewed publication or an institutional press release — Stanford Medicine press releases sometimes precede journal publication.
- Distinguish between common morning sickness (~70–80% of pregnancies) and hyperemesis gravidarum (~1–3% of pregnancies).
- Do not present association as causation — note study design (observational vs. other).
- Avoid alarming framing that could cause pregnant women to panic; emphasize treatability and the importance of seeking care.

**Key data points:** Stanford Medicine study (June 22, 2026) — retrieve journal DOI | HG affects ~1–3% of pregnancies | Associated with: birth complications, low birth weight, preterm birth (per study — confirm specifics) | Treatments: IV fluids, anti-nausea medications, vitamin B6.

**Sources:** Stanford Medicine (https://med.stanford.edu/news) — retrieve full release; journal [DOI — retrieve]; ACOG guidelines on nausea/vomiting in pregnancy (https://www.acog.org).

**SEO:** Primary: `severe nausea pregnancy complications` | Supporting: `hyperemesis gravidarum study 2026`, `morning sickness vs hyperemesis gravidarum`, `pregnancy nausea treatment`, `HG pregnancy risks`
**Format:** Research explainer + patient guide | **Word count:** 800–1,000 words
**Next steps:** Retrieve Stanford Medicine press release; find journal DOI; confirm study design and primary outcome; assign mid-week.

---

### BRIEF 8 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Patients bringing AI tools into therapy sessions — APA signals a trend"
primary_entity: "AI in mental health therapy"
signal_type: cultural_moment
allowed_category: "mental health and psychology"
trend_strength_score: 58
opportunity_score: 61
discover_score: 3
urgency: this_week
confidence: high
confidence_reason: >
  APA (American Psychological Association) is a tier-1 professional organization; this is
  not a social-only signal. Published June 25. Signal from single institutional source
  but APA carries strong credibility weight for this category.
content_status: new
source_count: 1
recommended_angle: >
  Balanced guide: how patients are using AI between therapy sessions, what therapists
  think about it, and what the research says about when AI helps vs. when it gets in the way.
why_now: >
  APA published this June 25. Mental health search interest is rising (+10% 7-day delta).
  AI tools like ChatGPT, Claude, and mental health apps are increasingly being used
  between or instead of therapy sessions — a practical, high-relevance topic for the audience.
primary_headline: "More Patients Are Bringing AI Into Therapy. Here's What Therapists Actually Think."
```

**Integrity flags:**
- ⚠️ Do not present AI as a substitute for professional mental health care.
- Distinguish between AI used as a journaling/reflection tool (lower risk) vs. AI being used for crisis support (higher risk — must note 988 Suicide and Crisis Lifeline).
- APA article may be commentary rather than a peer-reviewed study — confirm format before citing as research.
- No causal claims about outcomes; note the evidence base for AI mental health tools is still early-stage.

**Key data points:** APA published June 25, 2026 (https://www.apa.org) — retrieve article; Mental health search interest: +10% 7-day delta; Crisis resource: 988 Suicide and Crisis Lifeline.

**Sources:** APA (https://www.apa.org) — retrieve article | Existing peer-reviewed literature on AI mental health apps (search PubMed: "AI mental health therapy 2024–2026") | NIH/NIMH on digital mental health tools.

**SEO:** Primary: `AI therapy mental health` | Supporting: `ChatGPT therapy`, `AI mental health tools`, `using AI between therapy sessions`, `digital mental health apps`, `what therapists think about AI`
**Format:** Trend explainer + expert Q&A style | **Word count:** 800–1,000 words
**Next steps:** Retrieve APA article; determine if it's survey data, commentary, or clinical report; assign mid-to-late week.

---

## REJECTED TOPICS LOG

| Topic | Signal Source | Rejection Reason |
|---|---|---|
| Chris Evert (health queries) | Google Trends trending now | Celebrity health gossip — excluded category |
| Mitch McConnell health update | Google Trends rising query | Political celebrity health — excluded category |
| Sean Hannity health / health issues | Google Trends rising query | Political celebrity health — excluded category |
| Alka Yagnik health | Google Trends rising query | Celebrity health — excluded category; no clinical angle |
| Janice Dean health | Google Trends rising query | Celebrity health — excluded category |
| "What is wellness nook" / "wellness nook" | Google Trends rising | Product/local wellness facility — no health evidence angle; off category |
| "Civana wellness resort" | Google Trends rising | Wellness tourism / product marketing — excluded |
| "Kroma wellness" / "Stack wellness cafe" | Google Trends rising | Supplement marketing / brand promotion — excluded category |
| "Black girl wellness fest" | Google Trends rising | Event/community — no editorial health angle; off category |
| "Wellness gadgets" | Google Trends rising | Product marketing — excluded |
| USDA New World Screwworm detections | USDA APHIS radar | Veterinary/agricultural; no direct human health or zoonotic angle confirmed |
| LAPD wellness check dog fatality (BWC) | Police1 | Off-category entirely; law enforcement |
| Gotham FC / Nature's Garden wellness partnership | Gotham FC | Brand partnership / sports marketing — off category |
| Jamieson Wellness exploring sale | Bloomberg | Pure corporate M&A; no patient/health content angle |
| Saunas/cold plunges DIY wellness room | Business Insider | Lifestyle/wellness — lacks evidence base required by category rules |
| University wellness center announcements | Alfred, Penn State, UNC Asheville, Utah, Nebraska | Institutional PR — too narrow; no national health audience value |
| $24M Springfield sports/wellness center | Springfield News-Sun | Local facility — off category for national audience |
| Ketchikan Wellness Coalition Report | KRBD | Local/regional — off category |
| Cannabis Teamsters ULP Strike | Teamsters | Labor dispute — off category |
| Healthcare fraud takedown (DOJ/OIG) | DOJ.gov, OIG.gov | Law enforcement story; no direct patient health information value; monitored not retained |
| $50B rural health transformation fund | Healthcare Dive | Healthcare business/policy; insufficient patient-care angle for retention at this stage |
| LLMs outperform FDA-cleared clinical AI (Nature Medicine) | Clinical Trial Vanguard | Medical AI; niche for consumer audience; monitored — could develop as a future angle |
| Disparate privacy risks from medical AI | Nature | Abstract policy risk; no consumer action angle at this time; monitored |
| Health affordability midterms poll (Axios-Ipsos) | Axios | Pure political framing — excluded category |
| Health equity researcher scrutiny (STAT) | STAT News | Political/policy story without direct health information value |
| SNAP / supplemental nutrition assistance queries | Google Trends rising | Policy/benefits program — off category for health content |
| "How to read nutrition labels" | Google Trends rising | Useful evergreen; no breaking signal; defer to evergreen backlog |
| Nutrition product searches (Optimum Nutrition, etc.) | Google Trends rising | Product marketing — excluded |
| "Meat heavy diet" / "meat heavy diet name" | Google Trends rising | Query appears tied to crossword clue context, not genuine dietary interest — weak signal |
| "Baking soda and lemon juice for weight loss" | Google Trends rising | Unverified folk remedy — brand safety risk; would require 02b rejection if scored |
| "Does hormify work for weight loss" | Google Trends rising | Supplement claim with no identified primary source — would fail 02b gate |
| "Trump weight loss" | Google Trends rising | Political celebrity health — excluded category |
| General gut health (NPR microbiome article) | NPR | Good article but June 22; 4 days old; no new development; better as evergreen update candidate if not already covered |
| Cloud-based miniscope for neurosurveillance | Nature | Basic science / animal model — too technical and preliminary for consumer audience |
| AHRQ clinical development modernization | FDA.gov | Regulatory/process story without sufficient consumer angle to stand alone |
| Shockwave Medical carotid IVL studies | Cardiovascular Business | Medical device industry news — off category (pure business) |
| UVA Health MAC lung disease trial | WVIR | Single local trial announcement — off category for national audience |

---

## CONSOLIDATED INTEGRITY FLAGS

All ⚠️ flags for editorial review:

1. **BRIEF 1 — Chlorthalidone recall:**
   - 🔴 **Do NOT advise stopping the medication** without physician guidance. Abrupt discontinuation of blood pressure medication carries cardiovascular risk.
   - 🟡 Recall reason not yet confirmed — contamination, superpotency, and labeling errors require different editorial tones. Retrieve FDA notice first.
   - 🟡 Breaking-recall exception applied — lot codes and NDC numbers must be confirmed from FDA.gov before publishing.

2. **BRIEF 2 — CDC blocked COVID vaccine study:**
   - 🟡 Several outlets use "suppressed" / "doesn't want you to see" framing — do not replicate. Center the findings.
   - 🟡 Confirm whether study is observational or RCT; report sample size and primary outcome accurately.
   - 🟡 Study IS published; do not present as permanently blocked.

3. **BRIEF 3 — Statin muscle risk model:**
   - 🔴 **Do not publish before primary source (journal + DOI) is confirmed.** Signal is search-velocity driven; no primary outlet identified yet in radar.
   - 🟡 Statin rhabdomyolysis is rare (~0.01%); do not imply most statin users face serious risk.
   - 🟡 Distinguish mild myalgia (common, ~5–10%) from severe myopathy.

4. **BRIEF 4 — Operation TrialBlazer:**
   - 🟡 Phase 1 speed-up ≠ faster drug approvals. Do not conflate.
   - 🟡 Geopolitical "China threat" framing from some outlets — focus on patient access, not national competition.

5. **BRIEF 5 — Cancer study retraction:**
   - 🔴 **Do not cite the retracted study's findings as valid.** The retraction is the story.
   - 🟡 One retraction does not invalidate the entire field of circadian oncology research.
   - 🟡 Confirm retraction reason from NYT / journal retraction notice.

6. **BRIEF 6 — Listeria soft cheese:**
   - 🔴 **Do not name specific cheese brands without direct FDA confirmation.** Retrieve FDA outbreak notice first.
   - 🟡 Listeria incubation is 1–4 weeks — readers may have already consumed affected product; must include symptom guidance.
   - 🟡 High-risk groups (pregnant, elderly, immunocompromised) must be explicitly called out.

7. **BRIEF 7 — Pregnancy nausea / HG:**
   - 🟡 Confirm peer-reviewed publication vs. press release before citing as research.
   - 🟡 Association ≠ causation; note study design.
   - 🟡 Distinguish HG (~1–3%) from common morning sickness (~70–80%).

8. **BRIEF 8 — AI in therapy:**
   - 🟡 Do not present AI as a substitute for professional mental health care.
   - 🟡 Must include 988 Suicide and Crisis Lifeline for any piece on AI and mental health.
   - 🟡 APA source may be commentary — confirm whether peer-reviewed before characterizing as research.

---

## RUN NOTES

```yaml
run_date: "2026-06-26"
niche: "health and wellness"
signals_reviewed: 144
topics_retained: 8
topics_rejected: 136
p1_count: 1
p2_count: 3
p3_count: 4
p5_monitor_count: 4
integrity_flags: 15
top_topic: "Chlorthalidone blood pressure recall — 11,460 bottles"
key_themes:
  - "FDA drug recalls (chlorthalidone) — high consumer urgency"
  - "Institutional trust in public health agencies (CDC blocked study)"
  - "Clinical trial access and reform (HHS Operation TrialBlazer)"
  - "Statin safety personalization (muscle risk prediction)"
  - "Listeria food safety outbreak (soft cheese)"
  - "Medical study integrity (cancer circadian therapy retraction)"
  - "Hyperemesis gravidarum / pregnancy nausea validation"
  - "AI and mental health (patients + therapists)"
tools_used:
  - "SerpAPI Google News (pre-fetched)"
  - "SerpAPI Google Trends (pre-fetched, trending-now + 7-day interest)"
tools_unavailable: []
google_trends_available: true
google_trends_tool: "serpapi_prefetch"
search_velocity_source: "google_trends"
self_check_status: "skipped — site_url not configured; competitor-check fallback noted in candidate notes"
run_history_updated: false
notes: >
  data/run_history.yaml and data/deferred_topics.yaml were not readable in this session
  (no file system access in this execution context). Run history entry should be manually
  appended. No deferred topics were available to recheck.

  Google Trends trending-now list (statin muscle risk prediction, chlorthalidone recall,
  chris evert) was used as primary breakout signal for P1/P2 elevation.
  Chris Evert rejected — celebrity health; confirmed excluded category.

  Breaking-recall exception applied to both chlorthalidone recall and Listeria outbreak;
  confidence capped at Medium for both until primary FDA notices retrieved.

  Statin muscle risk prediction (Brief 3) carries a hard publishing gate — do not assign
  to writer until DOI/journal confirmed. Signal is search-velocity-only at this time.

  Monitored topics for future development:
  - 2026 healthcare fraud takedown (could develop as patient billing protection angle)
  - Medical AI privacy risks (could develop as patient-facing digital health angle)
  - LLMs vs. FDA-cleared clinical AI (could develop as health technology explainer)
  - $50B rural health fund (could develop as patient access / hospital closures angle)
```

---

**Dashboard generation note:** HTML file write to `outputs/daily_newsroom_dashboard/2026-06-26.html` and `data/run_history.yaml` update require file system access available in Claude Code (local execution). The full pipeline analysis, all briefs, and all structured data above are ready for that write step. Run the file-write block in Claude Code to complete the archival.